tiprankstipranks
Advertisement
Advertisement

SRPT Stock Latest News

Sarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
RatingsSarepta Therapeutics: Buy Rating Reiterated on Elevidys Uptake Outlook and Microdystrophin Validation; $35 Price Target Unchanged
6d ago
SRPT
Sarepta price target lowered to $19 from $20 at Evercore ISI
PremiumThe Fly
Sarepta price target lowered to $19 from $20 at Evercore ISI
6d ago
SRPT
FDA Commissioner Marty Makary resigns
PremiumThe Fly
FDA Commissioner Marty Makary resigns
9d ago
AZN
BMY
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
PremiumThe Fly
Trump Trade: Trump to suspend tariff-rate quotas on beef imports
9d ago
AZN
BMY
Trump Trade: U.S. plans AI security order without required model tests
PremiumThe Fly
Trump Trade: U.S. plans AI security order without required model tests
10d ago
DYN
RNA
Trump approves plan to fire FDA head Marty Makary, CBS reports
PremiumThe FlyTrump approves plan to fire FDA head Marty Makary, CBS reports
10d ago
DYN
RNA
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
Premium
Ratings
Sarepta Therapeutics: Pipeline Binary Risks and Elevidys Uptake Uncertainty Support Neutral Rating Through 2026
10d ago
SRPT
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
Premium
Ratings
Sarepta Therapeutics: Hold Rating Reaffirmed as Strong Elevidys Sales Offset by Pipeline and Execution Uncertainties
14d ago
SRPT
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
PremiumRatings
Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount
14d ago
SRPT
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
PremiumRatings
Sarepta Therapeutics: Safety Overhangs and Regulatory Uncertainty Reinforce Sell Rating and Unchanged $13 Price Target
14d ago
SRPT
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
PremiumRatings
Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward
14d ago
SRPT
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
PremiumThe Fly
Sarepta reports Q1 adjusted EPS $3.16 vs ($3.42) last year
15d ago
SRPT
Sarepta Therapeutics Signals Profits Amid Alevitus Tests
PremiumCompany AnnouncementsSarepta Therapeutics Signals Profits Amid Alevitus Tests
15d ago
SRPT
SRPT Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
SRPT Upcoming Earnings Report: What to Expect?
17d ago
SRPT
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
Premium
The Fly
Private Markets: Cursor in talks for $2B, Blue Energy secures $380M
28d ago
BA
BE
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
PremiumThe Fly
Roche decision could hurt Sarepta in U.S., says H.C. Wainwright
1M ago
CHRO
SRPT
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
PremiumThe Fly
Hemmati eyed for top vaccine and gene therapy regulator role, Bloomberg says
1M ago
DYN
RNA
Sarepta price target raised to $19 from $18 at RBC Capital
PremiumThe Fly
Sarepta price target raised to $19 from $18 at RBC Capital
1M ago
SRPT
Deutsche ups Sarepta target, says 35% stock rally overdone
PremiumThe Fly
Deutsche ups Sarepta target, says 35% stock rally overdone
2M ago
SRPT
Sarepta price target raised to $35 from $29 at Wedbush
PremiumThe FlySarepta price target raised to $35 from $29 at Wedbush
2M ago
SRPT
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
Premium
Ratings
Sell Rating on Sarepta: Strong siRNA Muscle Exposure Undermined by Weak Clinical Validation and ELEVIDYS Sales Risk
2M ago
SRPT
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
Premium
Ratings
Sarepta Therapeutics: Early TRiM Platform Promise Outweighed by High Clinical Risk and Valuation Downside, Justifying Sell Rating
2M ago
SRPT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >